Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACV1 for neuropathic sciatic pain
ACTRN12606000456550Phase 2Completed
- Sponsor
- Metabolic
- Start
- Sep 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of alpha-Conotoxin VC 1.1 in Sciatica and Neuralgia (2 arms), sponsored by Metabolic. Primary endpoints: Safety and tolerability of ACV1, Pharmacodynamic effects of ACV1 following single and multiple subcutaneous doses and 1 more. Started Sep 2006; status: completed.
02
Drugs
alpha-Conotoxin VC 1.1
03
Conditions
SciaticaNeuralgia
Beyond the preview
Go deeper on ACTRN12606000456550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000456550.